English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
Post-approval

Aloxi

Should clinicians always administer dexamethasone beyond 24h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies.
Authors:Celio L, Bonizzoni E, De Braud F, Agustoni F, Aapro M.
Source:Support Care Cancer. 2015 Aug 6. [Epub ahead of print].
Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Authors:Meattini I, Francolini G, Scotti V, De Luca Cardillo C, Cappelli S, Meacci F, Furfaro IF, Muntoni C, Scoccianti S, Detti B, Mangoni M, Nori J, Orzalesi L, Fambrini M, Bianchi S, Livi L.
Source:Med Oncol. 2015 Mar;32(3):80. doi: 10.1007/s12032-015-0535-9. Epub 2015 Feb 20.
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Authors:Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M.
Source:Future Oncol. 2014 Dec;10(16):2569-78. doi: 10.2217/fon.14.132.
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
Authors:De Tursi M, Carella C, Tomao S, Cinieri S, Lorusso V, Marchetti P, Vecchio S, Sansoni E, Contu A, Adamo V, Silvestris N, Nuzzo A, Rosti G, Ravaioli A, Danova M, Tonini G, Passalacqua R, Cruciani G, Faedi M, Spada M, De Laurentiis M, Amoroso D, Tomao F, Sperduti I, Grassadonia A, Tinari N, Natoli C, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia.
Source:Tumori. 2014 Nov-Dec;100(6):e309-13. doi: 10.1700/1778.19310.
Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron.
Authors:Celio L, de Braud F, Aapro M.
Source:J Clin Oncol. 2014 Jul 10;32(20):2185-6. doi: 10.1200/JCO.2014.55.4352.
Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.
Authors:Celio L, Agustoni F, Ricchini F, Dotti K, Niger M, Braud FD.
Source:Future Oncol. 2013 Oct;9(10):1451-8. doi: 10.2217/fon.13.153.
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Authors:Pacetti U, Veltri E, Fattoruso SI, Cardillo FD, Evangelista S, Cognetti F, Fabi A.
Source:Anticancer Res. 2013 Apr;33(4):1721-4.

Dropaxin

Benefit of slow titration of paroxetine to treat depression in the elderly.
Authors:Olgiati P, Bajo E, Serretti A; C.E.A.P (Cost-Effectiveness Analysis on Psychiatric Disorders) Group.
Source:Hum Psychopharmacol. 2014 Nov;29(6):544-51.
Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
Authors:Gibiino S, Mori E, De Ronchi D, Serretti A.
Source:J Clin Psychopharmacol. 2013 Aug;33(4):565-9.
Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.
Authors:Amodeo L, Castelli L, Leombruni P, Cipriani D, Biancofiore A, Torta R.
Source:Support Care Cancer. 2012 Feb;20(2):375-84.
Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial.
Authors:Buoli M, Dell'osso B, Bosi MF, Altamura C.
Source:Psychiatry Clin Neurosci. 2010 Dec;64(6):612-9.
Paroxetine drops versus paroxetine tablets: evaluation of compliance in a six-month study.
Authors:Zanardi R, Colombo L, Marcheggiani E, Rossini D, Delmonte D, Cigala Fulgosi M, Gavinelli C, Colombo C.
Source:Riv Psichiatr. 2013 May-Jun;48(3):261-7.

Endoprost

Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Authors:Foti R, Visalli E, Amato G, Benenati A, Converso G, Farina A, Bellofiore S, Mulè M, Di Gangi M.
Source:Rheumatol Int. 2016 Oct 28. [Epub ahead of print]
Efficacy, safety and feasibility of intravenous iloprost in the domiciliary treatment of patients with ischemic disease of the lower limbs
Authors:Polignano R, Baggiore C, Falciani F, Restelli U, Troisi N, Michelagnoli S, Panigada G, Tatini S, Farina A, Landini G.
Source:Eur Rev Med Pharmacol Sci 2016; 20 (17): 3720-6
User preference for a portable syringe pump for iloprost infusion.
Authors:Laria A, Lurati AM, Re KA, Marrazza MG, Mazzocchi D, Farina A, Scarpellini M.
Source:Patient Relat Outcome Meas. 2015 May 19;6:139-44. doi: 10.2147/PROM.S81473. eCollection 2015.
Iloprost infusion by a new device as a portable syringe pump: safety, tolerability and agreemen.
Authors:Faggioli P, Sciascera A, Giani L, Mazzone A.
Source:Italian Journal of Medicine (2012) 6, 311-14.
Effects of iloprost on pain-free walking distance and clinical outcome in patients with severe stage IIb peripheral arterial disease: the FADOI 2bPILOT Study.
Authors:Mazzone A, Di Salvo M, Mazzuca S, Valerio A, Gussoni G, Bonizzoni E, Campanini M, Vescovo G, Nozzoli C; FADOI 2bPILOT Study Group.
Source:Eur J Clin Invest. 2013 Nov;43(11):1163-70.
Acute limb ischemia in elderly patients: can iloprost be useful as an adjuvant to surgery? Results from the ILAILL study.
Authors:de Donato G, Gussoni G, de Donato G, Cao P, Setacci C, Pratesi C, Mazzone A, Ferrari M, Veglia F, Bonizzoni E, Settembrini P, Ebner H, Martino A, Palombo D; Ilaill Study Group.
Source:Eur J Vasc Endovasc Surg. 2007 Aug;34(2):194-8.
The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery.
Authors:de Donato G, Gussoni G, de Donato G, Andreozzi GM, Bonizzoni E, Mazzone A, Odero A, Paroni G, Setacci C, Settembrini P, Veglia F, Martini R, Setacci F, Palombo D.
Source:Ann Surg. 2006 Aug;244(2):185-93.

Ferplex Fol

Iron plus folate is more effective than iron alone in the treatment of iron deficiency anaemia in pregnancy: a randomised, double blind clinical trial.
Authors:Juarez-Vazquez J, Bonizzoni E, Scotti A.
Source:BJOG. 2002 Sep;109(9):1009-14.

Gelistrol

Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.
Authors:Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study.
Source:Maturitas 2016;83:40-4.
Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study.
Authors:Cagnacci A, Carbone MM, Palma F; AGATA study.
Source:Menopause 2016 Oct;23:1139-45.
Medical and patient attitude towards vaginal atrophy: the AGATA study.
Authors:Palma F, Della Vecchia E, Cagnacci A; as the Writing Group of the AGATA study.
Source:Climacteric 2016 Oct 13:1-5. [Epub ahead of print]
Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
Authors:Caruso S, Cianci S, Amore FF, Ventura B, Bambili E, Spadola S, Cianci A.
Source:Menopause. 2016;23:47-54.
A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive.
Authors:Serati M, Bogani G, Di Dedda MC, Braghiroli A, Uccella S, Cromi A, Ghezzi F.
Source:Eur J Obstet Gynecol Reprod Biol 2015;191:48-50.
The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
Authors:Cano A, Estévez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, Castellanos E, Moral E, Nieto C, del Prado JM, Ferrer J.
Source:Menopause. 2012 Oct;19(10):1130-9.
Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
Authors:López-Belmonte J, Nieto C, Estevez J, Delgado JL, del Prado JM.
Source:Maturitas. 2012 Aug;72(4):353-8. doi: 10.1016/j.maturitas.2012.05.007. Epub 2012 Jun 9. Erratum in: Maturitas. 2013 Apr;74(4):393.

Muphoran

Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.
Authors:Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Enrici RM.
Source:J Neurooncol. 2015 May;122(3):559-66.
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Authors:Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M.
Source:Ann Oncol. 2015 Apr;26(4):798-803.
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.
Authors:Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.
Source:Biomed Res Int. 2014;2014:351252.
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.
Authors:Nava F, Tramacere I, Fittipaldo A, Bruzzone MG, Dimeco F, Fariselli L, Finocchiaro G, Pollo B, Salmaggi A, Silvani A, Farinotti M, Filippini G.
Source:Neuro Oncol. 2014 May;16(5):719-27.
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
Authors:Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R.
Source:J Neurooncol. 2014 Feb;116(3):533-41.

Myelostim, Granocyte

Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience.
Authors:Marchesi F, Vacca M, Gumenyuk S, Pandolfi A, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Ipsevich F, Santinelli S, De Rienzo M, Papa E, Canfora M, Laurenzi L, Foddai ML, Pierelli L, Mengarelli A.
Source:Leuk Lymphoma. 2015 Jul 18:1-4. [Epub ahead of print].
Mobilization of hematopoietic stem cells with lenograstim in healthy donors: efficacy and safety analysis according to donor age.
Authors:Martino M, Bonizzoni E, Moscato T, Recchia AG, Fedele R, Gallo GA, Console G, Messina G, Morabito F.
Source:Biol Blood Marrow Transplant. 2015 May;21(5):881-8.
Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control.
Authors:Martino M, Moscato T, Barillà S, Dattola A, Pontari A, Fedele R, Furlò G, Marzia Stilo C, Alberto Gallo G, Tripepi G.
Source:Transfusion. 2015 Apr 9. doi: 10.1111/trf.13117. [Epub ahead of print].
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.
Authors:Rigacci L, Puccini B, Kovalchuk S, Fabbri E, Bonizzoni E, Perrone T, Bosi A.
Source:Support Care Cancer. 2014 Sep;22(9):2557-61.
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.
Authors:Ria R, Reale A, Melaccio A, Racanelli V, Dammacco F, Vacca A.
Source:Clin Exp Med. 2015 May;15(2):145-50.
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
Authors:Orciuolo E, Buda G, Marturano E, Mauro E, Milone G, Cangialosi C, Di Renzo N, Pastore D, Specchia G, De Paolis MR, Mazza P, Pietrantuono G, Petrini M.
Source:Leuk Res. 2011 Jul;35(7):899-903.

Natecal d3, Natemille

Adherence to Calcium and Vitamin D supplementations: results from the ADVICE Survey.
Authors:Conti F, Piscitelli P, Italiano G, Parma A, Caffetti MC, Giolli L, Di Tanna GL, Guazzini A, Brandi ML.
Source:Clin Cases Miner Bone Metab. 2012 Sep;9(3):157-60. Epub 2012 Dec 20.

Pletal

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.
Authors:de Franciscis S, Gallelli L, Battaglia L, Molinari V, Montemurro R, Stillitano DM, Buffone G, Serra R.
Source:Int Wound J. 2013 May 15.
Restenosis: a challenge for vascular surgeon.
Authors:Setacci C, Castelli P, Chiesa R, Grego F, Simoni GA, Stella A, Galzerano G, Sirignano P, De Donato G, Setacci F.
Source:J Cardiovasc Surg (Torino). 2012 Dec;53(6):735-46.

Seleparina, Seledie

Update on distal deep venous thrombosis. Reports of a multicenter study.
Authors:Guarnera G, Abeni D, Antignani PL, Apollonio A, Conti F, Mollo PL, Murgiano A, Ofria F, Ruggeri M.
Source:Int Angiol. 2014 Dec;33(6):560-4.
Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly.
Authors:Serra R, Buffone G, Molinari V, Montemurro R, Perri P, Stillitano DM, Amato B, de Franciscis S.
Source:Int Wound J. 2015 Apr;12(2):150-3.
The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival.
Authors:Barni S, Bonizzoni E, Verso M, Gussoni G, Petrelli F, Perrone T, Agnelli G.
Source:Blood. 2014 Jul 3;124(1):155-6.
Prophylaxis against venous thromboembolism in patients with cancer.
Authors:Verso M, Agnelli G.
Source:N Engl J Med. 2014 Sep 25;371(13):1262.
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.
Authors:Napolitano M, Saccullo G, Malato A, Sprini D, Ageno W, Imberti D, Mascheroni D, Bucherini E, Gallucci P, D'Alessio A, Prantera T, Spadaro P, Rotondo S, Di Micco P, Oriana V, Urbano O, Recchia F, Ghirarduzzi A, Lo Coco L, Mancuso S, Casuccio A, Rini GB, Siragusa S.
Source:J Clin Oncol. 2014 Nov 10;32(32):3607-12.
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Authors:Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators.
Source:Lancet Oncol. 2009 Oct;10(10):943-9.

Vasexten

Barnidipine real-life tolerability in arterial hypertension: results from the BASIC-HT study.
Authors:Lins R, Marckx P, Vandebeek R, Vanhoutvinck C, Neuville O.
Source:Acta Clin Belg. 2015 Aug;70(4):244-50. doi: 10.1179/2295333715Y.0000000012. Epub 2015 Mar 27.
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Authors:Derosa G, Querci F, Franzetti I, Dario Ragonesi P, D'Angelo A, Maffioli P.
Source:Hypertens Res. 2015 May 21. doi: 10.1038/hr.2015.57. [Epub ahead of print].
Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients.
Authors:Muiesan ML, Salvetti M, Belotti E, Paini A, Rosei CA, Aggiusti C, Scotti A, de Ciuceis C, Rizzoni D, Rosei EA.
Source:Blood Press. 2011 Aug;20(4):244-51.
Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-group study.
Authors:Parati G, Giglio A, Lonati L, Destro M, Ricci AR, Cagnoni F, Pini C, Venco A, Maresca AM, Monza M, Grandi AM, Omboni S.
Source:Clin Ther. 2010 Jul;32(7):1270-84.